Vision & Mission
Sera Prognostics aims to be a global leader in high-value women’s health diagnostics, delivering pivotal information to physicians to improve the health of pregnant women and newborns, and to simultaneously improve the economics.
Scientists at the University of Utah and Brigham Young University conducted early discovery activities for proteomic prediction of preterm delivery. A local seed investor licensed the discoveries from the Universities and formed Sera Prognostics.
First large institutional venture capital funding was secured, enabling the launch of the landmark PAPR study to discover, develop and validate the PreTRM® Test
Published broad U.S. validation of preterm birth risk prediction in the PAPR Study, in the American Journal of Obstetrics and Gynecology. Science recognized as highest quality and importance by AJOG Editor’s Choice award
Sera’s developmental pipeline expands to cover a number of important pregnancy conditions to enable Sera to become The Pregnancy Company®
Data-driven commercialization strategy developed in collaboration with the maternal-fetal medicine community providing the foundation to secure widespread payer coverage
Sera completes $100 million series E financing
Sera and Anthem announce partnership for commercial testing within Anthem network.
Published the results of a prospective, randomized controlled intervention trial, PREVENT-PTB. The study demonstrates the positive impact of the company’s PreTRM® test and treat strategy on improving neonatal healthcare